| Literature DB >> 26467984 |
Onur Gönül1, Tülin Satılmış2, Ferit Bayram2, Gökhan Göçmen2, Aysegül Sipahi2, Kamil Göker2.
Abstract
The aim of this study was to evaluate the effectiveness of submucosal application of tramadol, for acute postoperative facial pain, following the extraction of impacted third molar teeth. This prospective, double-blind, randomised placebo-controlled study included 60 ASA I-II patients undergoing impacted third molar surgery under local anaesthesia. Following the surgical procedure, patients were randomly divided into two groups; group T (1 mg/kg tramadol) and group S (2-mL saline). Treatments were applied submucosally after surgery. Pain after extraction was evaluated using a visual analogue scale (VAS) 0.5, 1, 2, 4, 6, 12, 24, and 48 h postoperatively. The time at which the first analgesic drug was taken, the total analgesic dose used, and adverse tissue reactions were also evaluated. In group T, postoperative VAS scores were significantly lower compared to that in group S (p < 0.05). This study demonstrated that post-operative submucosal application of tramadol is an effective method for reducing acute post-operative facial pain after impacted third molar surgery.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26467984 PMCID: PMC4606474 DOI: 10.1186/s13005-015-0090-9
Source DB: PubMed Journal: Head Face Med ISSN: 1746-160X Impact factor: 2.151
Patient characteristics, surgery time, total surgery time, visual analogue scale (VAS) scores, analgesic intake
| Group S | Group T | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | Mean | ± | SD | Test Value |
| |
| Age (years) | 23.93 | ± | 2.828 | 24.80 | ± | 2.524 | −1.252 | 0.215a |
| Height (cm) | 168.13 | ± | 8.033 | 168.23 | ± | 8.705 | −0.074 | 0.941b |
| Weight (kg) | 65.00 | ± | 10.286 | 64.93 | ± | 11.453 | −0.603 | 0.547b |
| ASA Grade | 1.00 | ± | 0.000 | 1.00 | ± | 0.000 | ||
| Total Surgery Time (min) | 48.00 | ± | 4.185 | 46.90 | ± | 4.528 | −1.141 | 0.254b |
| Surgery Time (min) | 26.27 | ± | 3.591 | 25.37 | ± | 3.306 | 1.01 | 0.317a |
| VAS 0.5 h | 0.00 | ± | 0.000 | 0.00 | ± | 0.000 | ||
| VAS 1 h | 6.37 | ± | 0.850 | 2.23 | ± | 0.898 | −6.755 | 0.0001b |
| VAS 2 h | 3.63 | ± | 0.615 | 1.87 | ± | 0.819 | −6.188 | 0.0001b |
| VAS 4 h | 3.07 | ± | 0.691 | 4.30 | ± | 1.264 | −4.714 | 0.0001b |
| VAS 6 h | 3.33 | ± | 1.446 | 1.77 | ± | 1.382 | −3.849 | 0.0001b |
| VAS 12 h | 0.63 | ± | 0.765 | 1.17 | ± | 0.791 | −2.668 | 0.008b |
| VAS 24 h | 0.23 | ± | 0.430 | 0.10 | ± | 0.305 | −1.374 | 0.169b |
| VAS 48 h | 0.07 | ± | 0.254 | 0.00 | ± | 0.000 | −1.426 | 0.154b |
| Initial Analgesic Intake | 1.87 | ± | 0.681 | 4.97 | ± | 0.809 | −6.779 | 0.0001b |
| Total Analgesic Intake | 3.60 | ± | 0.814 | 1.67 | ± | 0.547 | −6.47 | 0.0001b |
aStudent’s t-test (test value “t”)
bMann-Whitney U test (test value “Z”)
Patient characteristics and side-effects
| Test Value | df |
| ||||||
|---|---|---|---|---|---|---|---|---|
| Group S | Group T | |||||||
|
| % |
| % | |||||
| Gender | Female | 17 | 56.70 | 17 | 56.70 | 0.000 | 1 | 1.000 |
| Male | 13 | 43.30 | 13 | 43.30 | ||||
| Accompanying Disease | Absent | 30 | 100.00 | 30 | 100.00 | |||
| Present | 0 | 0.00 | 0 | 0.00 | ||||
| Nausea | Absent | 28 | 93.30 | 25 | 83.30 | 1.456 | 1 | 0.228 |
| Present | 2 | 6.70 | 5 | 16.70 | ||||
| Vomiting | Absent | 28 | 93.30 | 30 | 100.00 | 2.069 | 1 | 0.150 |
| Present | 2 | 6.70 | 0 | 0.00 | ||||
| Burning | Absent | 27 | 90.00 | 30 | 100.00 | 3.158 | 1 | 0.076 |
| Present | 3 | 10.00 | 0 | 0.00 | ||||
| Dizziness | Absent | 30 | 100.00 | 30 | 100.00 | |||
| Present | 0 | 0.00 | 0 | 0.00 | ||||
aPearson’s chi-squared test
Vital Signs of Groups
| Group S | Group T | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean | ± | SD | Mean | ± | SD | Test Value |
| |
| MBP 0. min | 60,10 | ± | 1,539 | 61,13 | ± | 1,717 | −2,455 | 0,017a |
| MBP 10. min | 60,77 | ± | 1,478 | 60,73 | ± | 1,337 | −0,008 | 0,994b |
| MBP 20. min | 60,37 | ± | 1,450 | 60,50 | ± | 1,009 | −0,183 | 0,855b |
| MBP 30. min | 60,60 | ± | 1,276 | 61,00 | ± | 0,910 | −1,536 | 0,125b |
| MBP 40. min | 60,60 | ± | 1,404 | 61,03 | ± | 1,299 | −1,24 | 0,220a |
| MBP 50. min | 60,47 | ± | 1,306 | 60,77 | ± | 1,382 | −0,864 | 0,391a |
| MBP 60. min | 60,57 | ± | 1,455 | 60,73 | ± | 1,413 | −0,45 | 0,654a |
| HR 0. min | 73,37 | ± | 2,988 | 73,00 | ± | 2,994 | 0,475 | 0,637a |
| HR 10. min | 73,67 | ± | 3,427 | 73,27 | ± | 3,129 | 0,472 | 0,639a |
| HR 20. min | 73,97 | ± | 3,306 | 73,83 | ± | 3,485 | 0,152 | 0,880a |
| HR 30. min | 74,27 | ± | 3,183 | 72,70 | ± | 2,215 | 2,213 | 0,031a |
| HR 40. min | 74,10 | ± | 3,377 | 73,07 | ± | 3,084 | 1,238 | 0,221a |
| HR 50. min | 74,27 | ± | 3,084 | 72,90 | ± | 2,998 | 1,74 | 0,087a |
| HR 60. min | 74,10 | ± | 3,033 | 74,17 | ± | 2,829 | −0,088 | 0,930a |
| SpO2 0. min | 98,73 | ± | 0,450 | 98,80 | ± | 0,407 | −0,605 | 0,545b |
| SpO2 10. min | 98,87 | ± | 0,346 | 98,77 | ± | 0,430 | −0,993 | 0,321b |
| SpO2 20. min | 98,87 | ± | 0,346 | 98,70 | ± | 0,466 | −1,554 | 0,120b |
| SpO2 30. min | 98,80 | ± | 0,407 | 98,80 | ± | 0,407 | 0 | 1,000b |
| SpO2 40. min | 98,77 | ± | 0,430 | 98,63 | ± | 0,490 | −1,117 | 0,264b |
| SpO2 50. min | 98,83 | ± | 0,379 | 98,73 | ± | 0,450 | −0,932 | 0,351b |
| SpO2 60. min | 98,80 | ± | 0,407 | 98,73 | ± | 0,450 | −0,605 | 0,545b |
aStudent’s t-test (test value “t”)
bMann-Whitney U test (test value “Z”)
MBP Mean Blood Pressure, HR Heart Rate, SpO2 Pheripheral Oxygen Saturation